| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/30/2013 | EP2549993A2 Antimicrobial compositions |
| 01/30/2013 | EP2549992A2 Methods of treatment using stem cell mobilizers |
| 01/30/2013 | EP2549991A1 Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias |
| 01/30/2013 | EP2549990A1 Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| 01/30/2013 | EP2549989A1 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media |
| 01/30/2013 | EP2549988A1 Fast dissolving drug delivery systems |
| 01/30/2013 | EP2549985A1 Stable pharmaceutical compositions comprising fesoterodine |
| 01/30/2013 | EP2549984A1 Double-layer pharmaceutical formulations containing opioid agonists and antagonists |
| 01/30/2013 | EP2549983A2 Novel composition for treatment of essential thrombocythemia |
| 01/30/2013 | EP2549982A1 Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe |
| 01/30/2013 | EP2549981A1 Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders |
| 01/30/2013 | EP2549875A1 Soluble guanylate cyclase activators |
| 01/30/2013 | EP2549874A1 Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors |
| 01/30/2013 | EP2549873A1 Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use |
| 01/30/2013 | EP2549872A1 Trpv4 antagonists |
| 01/30/2013 | EP2549871A1 Polymorphic forms st-246 and methods of preparation |
| 01/30/2013 | EP2549870A1 Process for preparing carbamoylpyridone derivatives and intermediates |
| 01/30/2013 | EP2549868A1 Chemical compounds |
| 01/30/2013 | EP2549867A1 Compositions and methods for prevention and treatment of wounds |
| 01/30/2013 | EP2549866A1 Endoparasiticidal compositions |
| 01/30/2013 | EP2549865A1 Sarms and method of use thereof |
| 01/30/2013 | EP2549863A1 Compositions and methods for glucose transport inhibition |
| 01/30/2013 | EP2406206B1 Tetrahydronaphthalen-2-ol derivatives |
| 01/30/2013 | CN202699645U Musk analgesic rheumatoid plaster |
| 01/30/2013 | CN202699643U Compound tamsulosin-finasteride capsule |
| 01/30/2013 | CN1997630B New disubstituted phenylpiperidines as modulators of dopamine neurotransmission |
| 01/30/2013 | CN1988912B Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| 01/30/2013 | CN1780611B Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
| 01/30/2013 | CN102906265A Lipid binding nucleic acids |
| 01/30/2013 | CN102906264A Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| 01/30/2013 | CN102906263A Compositions for controlling varroa mites in bees |
| 01/30/2013 | CN102906159A Amine polymers for use as bile acid sequestrants |
| 01/30/2013 | CN102906103A Compositions and methods for non-toxic delivery of antiprogestins |
| 01/30/2013 | CN102906102A Stereoselective synthesis of phosphorus containing actives |
| 01/30/2013 | CN102906099A (+)-3-hydroxymorphinan-based polycycle derivatives as neuroprotectants |
| 01/30/2013 | CN102906098A Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring |
| 01/30/2013 | CN102906095A Pyrrolopyrazine derivatives as SYK and JAK inhibitors |
| 01/30/2013 | CN102906093A Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| 01/30/2013 | CN102906092A Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
| 01/30/2013 | CN102906090A 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| 01/30/2013 | CN102906089A Compounds for the treatment of hepatitis C |
| 01/30/2013 | CN102906087A Process for the preparation of chiral triazolones |
| 01/30/2013 | CN102906086A Quinazoline compounds |
| 01/30/2013 | CN102906085A 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives |
| 01/30/2013 | CN102906083A Novel substituted triazole derivatives as gamma secretase modulators |
| 01/30/2013 | CN102906080A Compounds for the treatment of hepatitis C |
| 01/30/2013 | CN102906074A Fused imidazole derivative |
| 01/30/2013 | CN102905763A Lipids, lipid compositions, and methods of using them |
| 01/30/2013 | CN102905762A Methods and compositions for inducing satiety |
| 01/30/2013 | CN102905710A New biomaterial from wharton's jelly umbilical cord |
| 01/30/2013 | CN102905709A Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer |
| 01/30/2013 | CN102905708A A3ar agonists for the treatment of uveitis |
| 01/30/2013 | CN102905707A Pharmaceutical preparation comprising phenylalanine derivative |
| 01/30/2013 | CN102905706A Pharmaceutical composition containing solifenacin |
| 01/30/2013 | CN102905705A Novel iridium/rhodium anti-cancer compounds |
| 01/30/2013 | CN102905704A Sympatholytic agent, and cosmetic, food and sundry containing same |
| 01/30/2013 | CN102905703A Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases, etc. |
| 01/30/2013 | CN102905702A Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient |
| 01/30/2013 | CN102905701A 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases |
| 01/30/2013 | CN102905700A Compositions and methods for the prevention and treatment of cancer |
| 01/30/2013 | CN102905699A Anti-fungal agent |
| 01/30/2013 | CN102905698A Combination therapy comprising CCR5 antagonist, HIV-1 protease inhibitor and pharmacokinetic enhancer |
| 01/30/2013 | CN102905697A Compounds targeting VEGF and/or HIF pathway such as sorafenib or vatalanib for use in treatment of otitis media |
| 01/30/2013 | CN102905695A Preparations of biologically active substances with enlarged surface area based on amphiphilic copolymers |
| 01/30/2013 | CN102905694A Inhalation solutions |
| 01/30/2013 | CN102905693A Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids |
| 01/30/2013 | CN102905689A Liquid nasal spray containing low-dose naltrexone |
| 01/30/2013 | CN102905687A Orally disintegrating tablet containing acarbose |
| 01/30/2013 | CN102905680A Cosmetic and pharmaceutical composition comprising n-acetylglucosamine-6-phosphate |
| 01/30/2013 | CN102905542A Infant nutrition for improving fatty acid composition of brain membranes |
| 01/30/2013 | CN102905532A Methods and compositions for improving cognitive function |
| 01/30/2013 | CN102905529A Compositions comprising non-acidic boswellia oil fraction as bio-enhancer for enhancing the bioavailability of biological agents |
| 01/30/2013 | CN102905526A SARMS and method of use thereof |
| 01/30/2013 | CN102902895A Compound for preventing and treating human papillomavirus infection disease and screening method of compound |
| 01/30/2013 | CN102898542A Water-soluble fullerene and application thereof |
| 01/30/2013 | CN102898538A Abalone viscera acidic polysaccharose and health-care product containing abalone viscera acidic polysaccharose and application of abalone viscera acidic polysaccharose |
| 01/30/2013 | CN102898523A N-substituted-tetrahydropyridylindole-monoclonal antibody CD14 conjugates, and preparation method and application thereof |
| 01/30/2013 | CN102898522A Tetrahydropyridinopyran-monoclonal antibody CD14 conjugate with anti-tumor activity and preparation method and use thereof |
| 01/30/2013 | CN102898499A Benzopyran triterpene, medicinal composition thereof and preparation method and application of benzopyran triterpene |
| 01/30/2013 | CN102898497A Triterpenoid saponin compound extracted from clematis tangutica and application thereof |
| 01/30/2013 | CN102898478A High efficiency telomerase inhibitor and application of telomerase inhibitor in antitumor drug |
| 01/30/2013 | CN102898463A 2-hydroxy-N-(2-hydroxybenzoyl) benzo-hydrazide dibutyl tin complex and preparation method and application thereof |
| 01/30/2013 | CN102898452A Heterocyclic compound as TRPV1 blocker, pharmaceutical composition, and pharmaceutical use thereof |
| 01/30/2013 | CN102898438A Eutectic of Piperacillin sodium and Sulbactam sodium, preparation method thereof, pharmaceutical composition containing eutectic and application of pharmaceutical composition |
| 01/30/2013 | CN102898437A Acid-addition salt of Prasugrel, preparation method and application |
| 01/30/2013 | CN102898433A Tetrandrine gallate and drug composition, preparation method and applications thereof |
| 01/30/2013 | CN102898432A Tricyclic compound |
| 01/30/2013 | CN102898426A Pyrazolopyridine derivatives for inhibiting activity of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase |
| 01/30/2013 | CN102898425A 4,5-glyoxalidine [1,2-a] quinoline derivative and application of 4,5- glyoxalidine [1,2-a] quinoline derivative |
| 01/30/2013 | CN102898424A Novel polymorphs of dasatinib, and preparation method thereof |
| 01/30/2013 | CN102898417A Benzo-hexahydric nitrogenous heterocycle derivative |
| 01/30/2013 | CN102898416A 5-substituted quinazolinone derivatives as anti-cancer agents |
| 01/30/2013 | CN102898412A Anti-tumor and anti-bacterial dodecacyclo lactone compounds and use thereof |
| 01/30/2013 | CN102898408A Benzopyran compounds, preparation method and applications thereof |
| 01/30/2013 | CN102898403A Method for preparing novel crystal form of 1-(bi(4-fluorophenyl)methyl)-4-(2,3,4-trimethoxyphenyl)piperazine dihydrochloride |
| 01/30/2013 | CN102898402A Benzisoselenazolone-modified pyrrolyl formate-substituted indolone compound and use thereof |
| 01/30/2013 | CN102898400A GPR119 agonist and application thereof |
| 01/30/2013 | CN102898386A Quinazoline derivative, preparation method, intermediate, composition and application |
| 01/30/2013 | CN102898381A Amine salts of a CRTH2 antagonist |
| 01/30/2013 | CN102898380A Amine salts of a CRTH2 antagonist |